N-(3-methyl-4-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-3-nitrobenzamide

Catalog No. :
ACLXIG896
CAS No. :
1415560-17-6
Molecular Formula :
C23H18N6O3
Molecular Weight :
426.44

IUPAC Name:N-(3-methyl-4-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-3-nitrobenzamide

N-(3-methyl-4-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-3-nitrobenzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg98%$510.00Login to see priceInquiryInquiry
25mg98%$1274.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(3-methyl-4-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-3-nitrobenzamide
IUPAC NameN-(3-methyl-4-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-3-nitrobenzamide
MDL No.MFCD22571220
Molecular FormulaC23H18N6O3
Molecular Weight426.44
SMILESCC1=CC(NC(C2=CC=CC([N+]([O-])=O)=C2)=O)=CC=C1NC3=NC=CC(C4=CN=CC=C4)=N3
InChI KeyMCHLQASXFVTRQO-UHFFFAOYSA-N
SynonymN-(3-Methyl-4-(4-(pyridin-3-yl)pyriMidin-2-ylaMino)phenyl)-3-nitrobenzaMide
CAS No.1415560-17-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACLXIG896 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLXIG896 route product structure diagram
    ACLXIG8961415560-17-6
Inquiry

2. ACLXIG896 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACHAWG523 route compound structure diagram
    ACHAWG523483324-01-2 In Stock
  4. Then
  5. ACLXIG896 route product structure diagram
    ACLXIG8961415560-17-6
Inquiry

Comments (0)